In the process of cancer care, formulating a precise and personalized care plan has always been a major challenge. Traditional imaging and tumor marker tests are commonly used but often fail to comprehensively reflect the real-time dynamics and microscopic biological characteristics of tumors. With rapid advancements in liquid biopsy and genetic testing technologies, RGCC’s Onconomics Plus integrated analysis provides richer and more accurate data to support personalized care decisions, enabling healthcare teams to adjust care plans in a timely manner and ultimately improve patient prognosis and quality of life.

Advantages of Multidimensional Testing

1. Onconomics Plus Testing: Precise Evaluation of Targeted and Chemotherapy Drug Sensitivity
Onconomics Plus is a comprehensive tumor cell drug sensitivity test that evaluates a patient’s response to various targeted and chemotherapy drugs. By integrating circulating tumor cell (CTC) data with gene expression profiles, it provides precise drug matching recommendations that help healthcare teams select the most effective intervention strategies.

• Optimizing Targeted Therapy Choices: Based on test results, clinicians can choose drugs to which the patient shows higher sensitivity.
• Excluding Ineffective Options: If the test indicates low sensitivity to certain drugs, unnecessary or ineffective care strategies can be avoided, reducing side effects and economic burden.

2. Circulating Tumor Cell (CTC) Testing: Timely Capture of Tumor Dynamics
CTC testing analyzes the number and characteristics of tumor cells circulating in peripheral blood, reflecting the aggressiveness and metastatic potential of the tumor. Compared to traditional imaging, CTC testing is more sensitive and can detect metastasis risk before tumors are visible on scans.

• Early Warning of Recurrence and Metastasis: An increase in CTC count or cellular activity may indicate enhanced tumor activity, prompting early intervention.
• Assessing Care Effectiveness: A decrease in CTC count or cellular activity can serve as a biomarker for the efficacy of the care plan, providing guidance for optimization.

3. Tumor Stem Cell Testing: Predicting Drug Resistance and Recurrence Risk
Tumor stem cells (CSCs) possess self-renewal and proliferative capabilities and are closely related to tumor recurrence and drug resistance. RGCC testing can quantify the proportion and activity of CSCs, providing insights into potential drug resistance and recurrence risk.

• Guiding Drug Selection: A high proportion of CSCs may indicate strong drug resistance, necessitating adjustments in the intervention strategy or combination therapies.
• Predicting Recurrence: A persistent increase in tumor stem cell numbers may suggest a heightened risk of recurrence, indicating the need for enhanced monitoring or care plan adjustments.

Conclusion

Traditional imaging and tumor marker tests have limitations in reflecting the real-time dynamics of tumors. RGCC’s multidimensional testing integrated with Onconomics Plus, which encompasses CTC quantification, tumor stem cell activity, gene expression, and drug sensitivity, provides precise data support for personalized care decisions. By offering early warning of recurrence, guiding intervention choices, and optimizing care plans, this technology has the potential to improve long-term outcomes and quality of life for cancer patients.

References

1. Alix-Panabières, C., & Pantel, K. (2014). Challenges in circulating tumour cell research. Nature Reviews Cancer, 14(9), 623-631.
2. Yap, T. A., et al. (2022). Circulating tumour DNA and liquid biopsy in oncology. Nature Reviews Clinical Oncology, 19(10), 593-612.
3. Pantel, K., & Alix-Panabières, C. (2019). Liquid biopsy and minimal residual disease—latest advances and implications for cure. Nature Reviews Clinical Oncology, 16(7), 409-424.
4. Moutinho, C., et al. (2020). Personalized medicine in oncology: A review of clinical applications and challenges. Current Oncology Reports, 22(2), 13.
5. Keller, L., & Pantel, K. (2019). Unravelling tumour heterogeneity by single-cell profiling of circulating tumour cells. Nature Reviews Cancer, 19(10), 553-567.

Medical Disclaimer:

The information provided in this article is for educational and reference purposes only and does not constitute medical advice or be used as a substitute for professional medical diagnosis, treatment, or advice. ALWAYS CONSULT ANY QUESTIONS YOU MAY HAVE ABOUT YOUR MEDICAL CONDITION OR MEDICAL PROBLEM THAT YOU HAVE ALWAYS CONSULT YOUR PHYSICIAN OR OTHER QUALIFIED HEALTH PROFESSIONAL. The content of this article is not intended to recommend any specific test, treatment, or medication and should not be construed as such. If you develop symptoms or require medical assistance, please contact a healthcare professional promptly.